Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination

Hema Mohan, Anita Friese, Stefanie Albrecht, Markus Krumbholz, Christina L. Elliott, Ariel Arthur, Ramesh Menon, Cinthia Farina, Andreas Junker, Christine Stadelmann, Susan C. Barnett, Inge Huitinga, Hartmut Wekerle, Reinhard Hohlfeld, Hans Lassmann, Tanja Kuhlmann, Chris Linington, Edgar Meinl

Research output: Contribution to journalArticle

Abstract

Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of future MS therapies. Here we took a novel approach to identify factors that may inhibit or support endogenous remyelination in MS. We dissected remyelinated, demyelinated active, and demyelinated inactive white matter MS lesions, and compared transcript levels of myelination and inflammation-related genes using quantitative PCR on customized TaqMan Low Density Arrays. In remyelinated lesions, fibroblast growth factor (FGF) 1 was the most abundant of all analyzed myelination-regulating factors, showed a trend towards higher expression as compared to demyelinated lesions and was significantly higher than in control white matter. Two MS tissue blocks comprised lesions with adjacent de- and remyelinated areas and FGF1 expression was higher in the remyelinated rim compared to the demyelinated lesion core. In functional experiments, FGF1 accelerated developmental myelination in dissociated mixed cultures and promoted remyelination in slice cultures, whereas it decelerated differentiation of purified primary oligodendrocytes, suggesting that promotion of remyelination by FGF1 is based on an indirect mechanism. The analysis of human astrocyte responses to FGF1 by genome wide expression profiling showed that FGF1 induced the expression of the chemokine CXCL8 and leukemia inhibitory factor, two factors implicated in recruitment of oligodendrocytes and promotion of remyelination. Together, this study presents a transcript profiling of remyelinated MS lesions and identified FGF1 as a promoter of remyelination. Modulation of FGF family members might improve myelin repair in MS.

Original languageEnglish
Pages (from-to)168
Number of pages1
JournalActa neuropathologica communications
Volume2
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination'. Together they form a unique fingerprint.

  • Cite this

    Mohan, H., Friese, A., Albrecht, S., Krumbholz, M., Elliott, C. L., Arthur, A., Menon, R., Farina, C., Junker, A., Stadelmann, C., Barnett, S. C., Huitinga, I., Wekerle, H., Hohlfeld, R., Lassmann, H., Kuhlmann, T., Linington, C., & Meinl, E. (2014). Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta neuropathologica communications, 2, 168. https://doi.org/10.1186/s40478-014-0168-9